Corporate Information
Greetings
Corporate
Mission
Overview
Management
Business
Model
Locations
Corporate
Governance
History
Pipeline
What is “Regeneration-Inducing Medicine™”?
Chronicle of
Regeneration-Inducing Medicine™
Advantage of
Regeneration-Inducing Medicine™
Research Paper
Investor Relations
Stock Information
Financial Data
Presentation Materials
Sustainability at StemRIM
FAQ
Investor Library
JP
Inquiry
Corporate Information
Pipeline
About “Regeneration-Inducing Medicine™”
Investor Relations
Stock Information
Investor Library
Sustainability at StemRIM
JP
Inquiry
Investor Library
StemRIM
IR Library
Timely Disclosure Information
All Year
2025
2024
2023
2022
2021
All
Timely Disclosure Information
Financial Results
Presentation Materials
IR News
April 11, 2023
Timely Disclosure Information
[Delayed] StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke
<
1
2
3
4
5
